Does Age Impact Safety and Efficacy During Pulse‐Field Ablation for Atrial Fibrillation?

Background There is no evidence evaluating efficiency, effectiveness, and safety outcomes in older patients in the context of pulsed‐field ablation technology for the ablation of atrial fibrillation. We aimed to compare safety, efficacy, and acute and long‐term outcomes of pulsed‐field ablation in o...

Full description

Saved in:
Bibliographic Details
Main Authors: Antonio Dello Russo, Claudio Tondo, Stefano Bianchi, Vincenzo Schillaci, Saverio Iacopino, Michela Casella, Antonio Rossillo, Ruggero Maggio, Sakis Themistoclakis, Matteo Bertini, Maurizio Russo, Mario Volpicelli, Graziana Viola, Roberto Rordorf, Marco Schiavone, Yari Valeri, Jacopo Colella, Pietro Rossi, Fabrizio Tundo, Gianluca Zingarini, Antonio De Simone, Lorenzo Bianchini, Alessandro Di Vilio, Paolo Compagnucci, Maurizio Malacrida, Giulio Zucchelli, Francesco Solimene
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.037959
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850271201535983616
author Antonio Dello Russo
Claudio Tondo
Stefano Bianchi
Vincenzo Schillaci
Saverio Iacopino
Michela Casella
Antonio Rossillo
Ruggero Maggio
Sakis Themistoclakis
Matteo Bertini
Maurizio Russo
Mario Volpicelli
Graziana Viola
Roberto Rordorf
Marco Schiavone
Yari Valeri
Jacopo Colella
Pietro Rossi
Fabrizio Tundo
Gianluca Zingarini
Antonio De Simone
Lorenzo Bianchini
Alessandro Di Vilio
Paolo Compagnucci
Maurizio Malacrida
Giulio Zucchelli
Francesco Solimene
author_facet Antonio Dello Russo
Claudio Tondo
Stefano Bianchi
Vincenzo Schillaci
Saverio Iacopino
Michela Casella
Antonio Rossillo
Ruggero Maggio
Sakis Themistoclakis
Matteo Bertini
Maurizio Russo
Mario Volpicelli
Graziana Viola
Roberto Rordorf
Marco Schiavone
Yari Valeri
Jacopo Colella
Pietro Rossi
Fabrizio Tundo
Gianluca Zingarini
Antonio De Simone
Lorenzo Bianchini
Alessandro Di Vilio
Paolo Compagnucci
Maurizio Malacrida
Giulio Zucchelli
Francesco Solimene
author_sort Antonio Dello Russo
collection DOAJ
description Background There is no evidence evaluating efficiency, effectiveness, and safety outcomes in older patients in the context of pulsed‐field ablation technology for the ablation of atrial fibrillation. We aimed to compare safety, efficacy, and acute and long‐term outcomes of pulsed‐field ablation in older patients (≥75 years) with younger ones. Methods We enrolled consecutive patients who had undergone atrial fibrillation ablation with the pulsed‐field ablation FARAPULSE system (Boston Scientific) at 15 centers. Patients were stratified by age (<65, 65–74, and ≥75 years) and efficacy and safety profiles of these groups were compared. Results A total of 1082 patients were included: 108 (10%) were ≥75 years old, 374 (34.6%) were 65–74 years old and 600 (55.4%) were <65 years old. Older patients displayed a more pronounced risk profile compared with their younger counterparts, characterized by a significant higher burden of comorbidities. No differences in terms of procedural metrics were found. Pulmonary vein isolation was achieved in all patients. An overall low rate of procedural‐related complications was reported (3.0%) without difference between young and older patients (P=0.241). During a mean follow‐up of 342±111 days, a primary efficacy end point occurred in 605 of 748 (80.9%) patients with available outcome information. The arrhythmia recurrence rate ranged from 14.4% in patients <65 years old to 26.9% of older patients (P=0.011). Conclusions Drawing from these findings, using the FARAPULSE system for atrial fibrillation ablation in older patients demonstrated swift, safe, and effective acute outcomes, mirroring a comparable pattern observed in younger patients and recurrence rates in line with the literature in older patients. Registration URL: clinicaltrials.gov; Unique Identifier: NCT05617456.
format Article
id doaj-art-2c66579c6edc496bb81d689cd1c99354
institution OA Journals
issn 2047-9980
language English
publishDate 2025-05-01
publisher Wiley
record_format Article
series Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
spelling doaj-art-2c66579c6edc496bb81d689cd1c993542025-08-20T01:52:19ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-05-0114910.1161/JAHA.124.037959Does Age Impact Safety and Efficacy During Pulse‐Field Ablation for Atrial Fibrillation?Antonio Dello Russo0Claudio Tondo1Stefano Bianchi2Vincenzo Schillaci3Saverio Iacopino4Michela Casella5Antonio Rossillo6Ruggero Maggio7Sakis Themistoclakis8Matteo Bertini9Maurizio Russo10Mario Volpicelli11Graziana Viola12Roberto Rordorf13Marco Schiavone14Yari Valeri15Jacopo Colella16Pietro Rossi17Fabrizio Tundo18Gianluca Zingarini19Antonio De Simone20Lorenzo Bianchini21Alessandro Di Vilio22Paolo Compagnucci23Maurizio Malacrida24Giulio Zucchelli25Francesco Solimene26Department of Biomedical Sciences and Public Health Marche Polytechnic University Ancona ItalyMonzino Cardiological Center Milan ItalyCenter of Excellence in Cardiovascular Sciences Ospedale Isola Tiberina ‐ Gemelli Isola Rome ItalyMontevergine Clinic Mercogliano AV ItalyMaria Cecilia Hospital, GVM Care &amp; Research Cotignola RA ItalyDepartment of Cardiology and Arrhythmology Clinic Marche University Hospital Ancona ItalySan Bortolo Hospital Vicenza ItalyDegli Infermi Hospital Rivoli TO ItalyDell’Angelo Hospital Mestre VE ItalyCardiology Unit, University of Ferrara Sant’Anna University Hospital Ferrara ItalySan Filippo Neri Hospital Rome ItalyCardiovascular Diseases and Electrophysiology Unit S. Maria della Pietà Hospital Nola, Naples ItalyClinical and Experimental Cardiology, Clinical and Interventional Cardiology University Hospital Sassari ItalyArrhythmia and Electrophysiology Unit, Division of Cardiology Fondazione IRCCS Policlinico San Matteo Pavia ItalyMonzino Cardiological Center Milan ItalyDepartment of Cardiology and Arrhythmology Clinic Marche University Hospital Ancona ItalyMaria Cecilia Hospital, GVM Care &amp; Research Cotignola RA ItalyCenter of Excellence in Cardiovascular Sciences Ospedale Isola Tiberina ‐ Gemelli Isola Rome ItalyMonzino Cardiological Center Milan ItalyS. Maria della Misericordia Hospital Perugia ItalyS. Michele Clinic Maddaloni CE ItalyMonzino Cardiological Center Milan ItalyMaria Cecilia Hospital, GVM Care &amp; Research Cotignola RA ItalyDepartment of Biomedical Sciences and Public Health Marche Polytechnic University Ancona ItalyBoston Scientific Milan ItalySecond Division of Cardiology, Cardiac‐Thoracic‐Vascular Department New Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana Pisa ItalyDepartment of Biomedical Sciences and Public Health Marche Polytechnic University Ancona ItalyBackground There is no evidence evaluating efficiency, effectiveness, and safety outcomes in older patients in the context of pulsed‐field ablation technology for the ablation of atrial fibrillation. We aimed to compare safety, efficacy, and acute and long‐term outcomes of pulsed‐field ablation in older patients (≥75 years) with younger ones. Methods We enrolled consecutive patients who had undergone atrial fibrillation ablation with the pulsed‐field ablation FARAPULSE system (Boston Scientific) at 15 centers. Patients were stratified by age (<65, 65–74, and ≥75 years) and efficacy and safety profiles of these groups were compared. Results A total of 1082 patients were included: 108 (10%) were ≥75 years old, 374 (34.6%) were 65–74 years old and 600 (55.4%) were <65 years old. Older patients displayed a more pronounced risk profile compared with their younger counterparts, characterized by a significant higher burden of comorbidities. No differences in terms of procedural metrics were found. Pulmonary vein isolation was achieved in all patients. An overall low rate of procedural‐related complications was reported (3.0%) without difference between young and older patients (P=0.241). During a mean follow‐up of 342±111 days, a primary efficacy end point occurred in 605 of 748 (80.9%) patients with available outcome information. The arrhythmia recurrence rate ranged from 14.4% in patients <65 years old to 26.9% of older patients (P=0.011). Conclusions Drawing from these findings, using the FARAPULSE system for atrial fibrillation ablation in older patients demonstrated swift, safe, and effective acute outcomes, mirroring a comparable pattern observed in younger patients and recurrence rates in line with the literature in older patients. Registration URL: clinicaltrials.gov; Unique Identifier: NCT05617456.https://www.ahajournals.org/doi/10.1161/JAHA.124.037959ageatrial fibrillationelectroporationolder patientspulsed‐field ablation
spellingShingle Antonio Dello Russo
Claudio Tondo
Stefano Bianchi
Vincenzo Schillaci
Saverio Iacopino
Michela Casella
Antonio Rossillo
Ruggero Maggio
Sakis Themistoclakis
Matteo Bertini
Maurizio Russo
Mario Volpicelli
Graziana Viola
Roberto Rordorf
Marco Schiavone
Yari Valeri
Jacopo Colella
Pietro Rossi
Fabrizio Tundo
Gianluca Zingarini
Antonio De Simone
Lorenzo Bianchini
Alessandro Di Vilio
Paolo Compagnucci
Maurizio Malacrida
Giulio Zucchelli
Francesco Solimene
Does Age Impact Safety and Efficacy During Pulse‐Field Ablation for Atrial Fibrillation?
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
age
atrial fibrillation
electroporation
older patients
pulsed‐field ablation
title Does Age Impact Safety and Efficacy During Pulse‐Field Ablation for Atrial Fibrillation?
title_full Does Age Impact Safety and Efficacy During Pulse‐Field Ablation for Atrial Fibrillation?
title_fullStr Does Age Impact Safety and Efficacy During Pulse‐Field Ablation for Atrial Fibrillation?
title_full_unstemmed Does Age Impact Safety and Efficacy During Pulse‐Field Ablation for Atrial Fibrillation?
title_short Does Age Impact Safety and Efficacy During Pulse‐Field Ablation for Atrial Fibrillation?
title_sort does age impact safety and efficacy during pulse field ablation for atrial fibrillation
topic age
atrial fibrillation
electroporation
older patients
pulsed‐field ablation
url https://www.ahajournals.org/doi/10.1161/JAHA.124.037959
work_keys_str_mv AT antoniodellorusso doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT claudiotondo doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT stefanobianchi doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT vincenzoschillaci doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT saverioiacopino doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT michelacasella doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT antoniorossillo doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT ruggeromaggio doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT sakisthemistoclakis doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT matteobertini doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT mauriziorusso doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT mariovolpicelli doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT grazianaviola doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT robertorordorf doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT marcoschiavone doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT yarivaleri doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT jacopocolella doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT pietrorossi doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT fabriziotundo doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT gianlucazingarini doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT antoniodesimone doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT lorenzobianchini doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT alessandrodivilio doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT paolocompagnucci doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT mauriziomalacrida doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT giuliozucchelli doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation
AT francescosolimene doesageimpactsafetyandefficacyduringpulsefieldablationforatrialfibrillation